STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to drop in at a few musical happenings, promenade with the official mascots, and hang with the Pharmalot ancestor. We also will be making time for yet another listening party, where the rotation will likely include this, this, this, this and this. And what about you? Once again, we will remind you that this is a fabulous time to enjoy the great outdoors. An added bonus, of course, is you can get some exercise, too. If the weather fails to cooperate, though, you could visit your local library and curl up with a good book. Or take in a moving picture show at whatever cinema may still exist in your part of the world. If none of this sounds appealing, well, you could simply plan the rest of your life. Whatever you do, have a grand time. But be safe. Enjoy, and see you soon … Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals, STAT reports. The meeting, between U.S. Trade Representative Jamieson Greer, chief health department adviser Chris Klomp, and German Ambassador Jens Hanefeld, was part of a larger push from the Trump administration to get other countries to pay more for medications as the U.S. pays less, according to a person familiar with the meeting. The U.S. officials discussed the possible use of tariffs under Section 301, which grants the government authority to combat trade practices considered “unfair.” The move would be similar to the tactic of threatening new tariffs to get other countries to pay more for drugs. The ambassador agreed to review the matter with officials in Germany, but no deal was made. Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs and policy changes at the drugs